Treatment with PKI-587 and imatinib mesylate effectively inhibited the phosphorylation of Akt and mTOR in PDX tumours, and imatinib inhibited PDGFRB phosphorylation (Fig. 5h, i). Here, AKT1 is linked to neoplasm.